Cancer News

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer (02/18/2019)

The Food and Drug Administration (FDA) approved the immunotherapy drugs Opdivo and Yervoy in combination as an initial, or first-line, treatment for patients with advanced kidney cancer whose disease has an intermediate or poor prognosis. This is the first immunotherapy regimen to be approved by FDA for the initial treatment of patients with kidney cancer.... Continue Reading

Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer (02/18/2019)

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda (pembrolizumab) and the VEGF-targeted tyrosine kinase inhibitor Inlyta (axitinib) improved overall survival and delayed cancer progression-free for patients with clear-cell metastatic renal cell carcinoma, compared to the current standard of care, Sutent (sunitinib).... Continue Reading

Personalized Vaccine to be Tested in Patients with Kidney Cancer (01/29/2019)

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery. This two-pronged approach to mobilizing a... Continue Reading

Tivozanib for Renal Cell Cancer (11/16/2018)

The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC). About tivozanib Tivozanib is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. In the current clinical trial, 351 patients with advanced RCC were treated with either tivozanib or Nexavar (sorafenib) and directly compared.  The …

Continue reading "Tivozanib for Renal Cell Cancer"

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer (04/23/2018)

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than …

Continue reading "FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer"

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma (01/25/2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are …

Continue reading "Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma"

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma (01/05/2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx™ (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy.  The FDA previously approved Cabometyx in 2016 for treatment of …

Continue reading "FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma"

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer (11/09/2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each …

Continue reading "Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer"

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma (06/19/2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy.  CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in Phase 1/2 clinical …

Continue reading "FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma"

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer (03/01/2017)

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical trial.1 According to investigators, 25% of RCC patients responded to treatment with the combination and this represents an …

Continue reading "Dalantercept- Inlyta Shows Promise for Renal Cell Cancer"